BioReview

Biotechnology

Ipsen's Revolutionary Cancer Immunotherapy Earns FDA Breakthrough Status in Blood Cancer Fight

In a significant advancement for cancer immunotherapy, French pharmaceutical company Ipsen announced on January 13, 2026, that the FDA has granted Breakthrough Therapy Designation to IPN60340 (ICT01), a first-in-class monoclonal antibody targeting acute myeloid leukemia (AML). This regulatory milestone positions the therapy as a potentially transformative treatment for one of

Inspira’s Recent Moves Signal a a Broader Play Around Real-Time Blood Intelligence

Inspira Technologies (NASDAQ: IINN) is a medical technology company operating in critical care environments. Its lead product, the ART100 system, has received U.S. Food and Drug Administration clearance for use during cardiopulmonary bypass procedures in cardiac surgery. The company has been working toward broader commercialization, with previously disclosed purchase

Pharmaceuticals

Historic FDA Approval: Zycubo Becomes First Treatment for Menkes Disease, Delivering 10-Fold Survival Improvement

Sentynl Therapeutics receives FDA approval for Zycubo, the first and only treatment for Menkes disease, offering a 10-fold improvement in survival for children with this devastating rare genetic disorder.

Biotechnology

Chinese Biotech Abbisko Challenges Established Players in Rare Tumor Market as FDA Accepts Pimicotinib Application

Abbisko Therapeutics' FDA acceptance of pimicotinib NDA marks a significant regulatory milestone in the competitive TGCT market, challenging established players like Deciphera and Daiichi Sankyo.

RFK Is Changing How America Thinks About Health. This MicroCap May Be Built for What Comes Next

Why a prevention-first reset could benefit platforms like DarioHealth When Robert F. Kennedy Jr. unveiled a sweeping overhaul of U.S. dietary guidelines in early 2026, the announcement barely mentioned technology companies or digital health platforms. Yet buried inside the policy shift - away from ultra-processed foods and toward whole,

Biotechnology

Beyond Weight Loss: French Biotech Pioneers First-in-Class GLP-1 Therapy for Joint Disease as Osteoarthritis Market Awaits Its First Disease-Modifying Drug

French biotech 4Moving Biotech achieves FDA IND clearance for 4P004, a first-in-class intra-articular GLP-1 therapy targeting osteoarthritis, potentially becoming the first disease-modifying osteoarthritis drug (DMOAD) to reach patients.

Biotechnology

Oculis Achieves Historic Breakthrough: FDA Grants First-Ever Neuroprotective Therapy Designation for Optic Neuritis

In a landmark achievement that could transform treatment for one of neuro-ophthalmology's most challenging conditions, Oculis Holding AG announced on January 6, 2026, that the FDA has granted Breakthrough Therapy Designation to Privosegtor for the treatment of optic neuritis. This designation marks the first time any investigational therapy

Biotechnology

Revolution Medicines Achieves Historic First: FDA Grants Breakthrough Therapy Designation for KRAS G12D-Targeted Cancer Drug

Revolution Medicines announces FDA Breakthrough Therapy Designation for zoldonrasib, marking the first investigational drug specifically targeting the KRAS G12D mutation to receive this prestigious regulatory recognition.

Biotechnology

Krystal Biotech's Gene Therapy Breakthrough: KB407 Shows Promise in Addressing Cystic Fibrosis at Its Genetic Root

Krystal Biotech announces interim clinical results from its Phase 1 CORAL-1 study of KB407, a potentially mutation-agnostic gene therapy for cystic fibrosis that could transform treatment for all CF patients.

Hypothalamic Obesity Is Emerging as the Next Frontier in Obesity Drug Development - and Palatin Is Worth Watching

For most investors, “obesity drugs” now means GLP-1s. But not all obesity is lifestyle-driven, and not all patients respond to incretins - hormone-based drugs like GLP-1s that suppress appetite. One of the most severe and underserved forms of obesity - hypothalamic obesity (HO) - sits largely outside the GLP-1 boom.

Biotechnology

Jazz Pharmaceuticals' Ziihera Achieves Unprecedented Survival in Gastric Cancer: Over Two Years Median Overall Survival Marks New Treatment Paradigm

Jazz Pharmaceuticals announces unprecedented survival outcomes for Ziihera in HER2-positive gastroesophageal adenocarcinoma, achieving over two years median overall survival—the longest ever reported in a Phase 3 trial for this disease.

Why One of Lung Cancer’s Best Drugs Eventually Stops Working- and How Nuvectis Pharma Is Trying to Fix That

In modern oncology, progress is often defined less by discovering new drugs than by understanding why good drugs stop working. Few therapies illustrate that challenge more clearly than AstraZeneca’s Tagrisso (osimertinib), the backbone treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Tagrisso generates more than $6 billion